Pharsight

Ultravate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962028 SUN PHARM INDUSTRIES Topical steroid composition and method
Jun, 2033

(9 years from now)

Ultravate is owned by Sun Pharm Industries.

Ultravate contains Halobetasol Propionate.

Ultravate has a total of 1 drug patent out of which 0 drug patents have expired.

Ultravate was authorised for market use on 06 November, 2015.

Ultravate is available in lotion;topical dosage forms.

Ultravate can be used as use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis.

The generics of Ultravate are possible to be released after 19 June, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 06, 2018
New Patient Population(NPP) Aug 31, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2015

Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis

Dosage: LOTION;TOPICAL

How can I launch a generic of ULTRAVATE before it's drug patent expiration?
More Information on Dosage

ULTRAVATE family patents

Family Patents